Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06576115 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Gemcitabine, Nab-paclitaxel Plus the TheraBionic P1 (an Amplitude-Modulated Radiofrequency Electromagnetic Fields) Device to Treat Metastatic Pancreatic Cancer

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Re-verified, no change to tracked fieldsv5
  2. Study sites: 1 to 7v4
  3. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Mar 2025 to Feb 28, 2025
    • Site details revised
    v3
  4. Start date: Oct 2024 to Mar 2025
    • Site contact updated
    v2
  5. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The goal of this study is to learn if the combination of nab-paclitaxel, gemcitabine and an Amplitude-Modulated Radiofrequency Electromagnetic Fields device (Therabionic P1) is safe and effective for patients with adenocarcinoma of the pancreas.
Trial Details
NCT Number NCT06576115
Lead Sponsor Barbara Ann Karmanos Cancer Institute
Conditions
(from sponsor)		 Metastatic Pancreatic Adenocarcinoma
Enrollment 30 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov